Share
News
-
11 March 2010 /Product information
Strengthened warning against Alscreme 'Creme nr. 2' from www.eminescu.dk
On 12 February 2010, the Danish Medicines Agency warned strongly against using the product Alscreme 'Creme nr. 2' sold via www.eminescu.dk, as the product is an unlicensed medicinal product that contains active substance clobetasol.
-
03 March 2010 /Product information
Updating of summary of product characteristics prompted by changed ATC codes for 2010
Marketing authorisation holders of medicinal products authorised under the Decentralised Procedure and the Mutual Recognition Procedure should be aware that som ATC codes have been changed in 2010.
-
16 February 2010 /Product information
Warning against ‘Alscreme Creme nr. 2’ from www.eminescu.dk
The Danish Medicines Agency warns strongly against use of the product 'Alscreme Creme nr. 2' sold via www.eminescu.dk, as the product is an unauthorised medicinal product containing the active substance clobetasol.
-
29 January 2010 /Product information
Warning against pills from IDS Sports
The Danish Medicines Agency and the Danish Veterinary and Food Administration warn against use of the Bromodrol, Dual Action Grow Tabs, Grow Tabs, Mass Tabs and Ripped Tabs TR.
-
22 December 2009 /Product information
Warning against the potency-enhancing product Rock Hard Weekend
The Danish Medicines Agency strongly warns against using the potency-enhancing product Rock Hard Weekend after the FDA (U.S. Food and Drug Administration) has notified the Danish Medicines Agency that Rock Hard Weekend contains an undeclared active substance and that the product has been exported from the USA to Denmark.
-
09 December 2009 /Product information
Warning against the weight-loss product Super Slim
The Danish Medicines Agency strongly warns against using the weight-loss product Super Slim. We do so based on a warning from the Swedish Medical Products Agency against Super Slim, which is sold on the internet.
-
26 August 2009 /Product information
Danish Medicines Agency hosts conference on biosimulation
Christiansborg Palace in Copenhagen sets the scene for a three-day conference where a group of leading scientists meet to take stock of recent years' progress of using computer modelling to develop medicines, an area also known as biosimulation.
-
11 May 2009 /Product information
Extended use of Tamiflu®
The European Medicines Agency, EMEA, has reassessed the use of Tamiflu® in pregnant women and infants who are ill with influenza A(H1N1).
-
07 May 2009 /Product information
Warning on Hydroxycut pills
Stop using Hydroxycut pills, powder and capsules and talk to your doctor about possible side effects or symptoms of liver damage (jaundice, darkening of urine, nausea, vomiting, light-coloured stools, excessive fatigue, stomach or abdominal pain, itching and loss of appetite).
-
04 May 2009 /Product information
Alli® (orlistat) – over-the-counter weight-loss product
From today, pharmacies across Denmark will be offering the weight-loss product Alli®. Alli® contains the active ingredient orlistat, which has been authorised in Denmark and other EU countries since 1998 as a prescription-only weight-loss product.
-
03 April 2009 /Product information
Withdrawal of the NES-Spacer® from AstraZeneca A/S
AstraZeneca has identified a problem with the NES-Spacer®, which is an inhalation device to be used together with asthma medicine. If a patient assembles the NES-Spacer® incorrectly, the patient cannot inhale the medicine, and the simultaneous use of a face mask prevents the patient from breathing.
-
13 January 2009 /Product information
Scabies medicine on its way to Denmark
The many cases of scabies all over Denmark has led to a lack of the medicine, Nix, which is authorised for scabies treatment in Denmark. In cooperation with the Assocation of Danish Pharmacies and the Danish Medicines Agency, the importer has come up with a solution which will ensure relief this week.
-
19 September 2008 /Product information
National meeting about the Pharmaceutical Forum held 12 September 2008
On 12 September 2008, the Danish Medicines Agency hosted a national meeting about the Pharmaceutical Forum held by the Danish Ministry of Health and Prevention and the Danish Medicines Agency.
-
12 September 2008 /Product information
Withdrawal of the asthma and lung medicine Oxis Turbohaler® with batch no. IA763-3
2care4 has, in cooperation with the Danish Medicines Agency, chosen to withdraw Oxis Turbohaler® with batch no. IA763-3 from Danish pharmacies. The company has chosen to do so because of the risk that packages in this batch may contain turbohalers with the wrong dose relative to the strength stated on the package.
-
27 August 2008 /Product information
Thalidomide Pharmion (thalidomide) on the Danish market as of 25 August 2008
Thalidomide Pharmion is authorised in the EU as first line treatment of multiple myeloma, which is a relatively rare cancer of the bone marrow. Thalidomide Pharmion must be given in combination with the medicines melphalan and prednisone.
-
11 August 2008 /Product information
Warning against the product Melanotan
The Danish Medicines Agency has been made aware of the product, Melanotan, which is sold via the internet. The product is marketed as a product that increases pigmentation, providing tanned skin and protection against the harmful rays of the sun, implying that it may prevent skin cancer. However, this effect has not been documented.
-
25 July 2008 /Product information
EMEA recommends restricting the use of oral moxifloxacin-containing medicines
The European Medicines Agency (EMEA) has reviewed the safety of moxifloxacin-containing medicines for oral use. The EMEA has concluded that these medicines should only be prescribed for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia when other antibiotics cannot be used or have failed.
-
25 July 2008 /Product information
EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections
The European Medicines Agency has recommended restricting the use of oral norfloxacin-containing medicines in urinary infections.
-
25 July 2008 /Product information
No increased risk of developing cancer for patients having taken Viracept® contaminated with ethyl mesilate
Following a review of a number of toxicology studies, the European Medicines Agency (EMEA) has confirmed that there is no increased risk of development of cancer for patients who have taken contaminated Viracept® (Nelfinavir).
-
15 July 2008 /Product information
Warning against the product Viamax Energizer
The Danish Medicines Agency has become aware of the product Viamax Energizer, which is sold on the internet as a product providing energy. An analysis carried out by the Swedish Medical Products Agency has shown that the product contains the active substances levodopa and theophylline, which does not appear from the packages.
